BioSpace Movers & Shakers, Oct. 16

Montage life sciences – Former Gilead Sciences CSO John McHutchison, currently President and CEO of the Congregation, has been named a recipient of the Advance 2020 Global Impact Award. The Advance Awards recognize the work of remarkable global Australians who make an exceptional impact around the world. The award recognizes McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus.

BeyondSpring BeyondSpring Inc. formed a partnership advisory board comprised of former multinational pharmaceutical veterans and industry leaders. The committee’s role is to support BeyondSpring’s business development activities in relation to its primary assets, Plinabulin and other pipeline assets. Mukul Agarwal, former vice president of corporate development at Forty Seven, Inc., and Daniel Zabrowski, former global head of Pharma Partnering at Roche and current board member of BeyondSpring, have been named first committee members. The company expects to nominate additional members over time.

Axovant – Kristin Vuori has been appointed to the Board of Directors of Axovant Gene Therapies Ltd. called. Vuori is a professor at the Sanford Burnham Prebys Medical Discovery Institute, where she also serves as president and board member. In addition, Parag V. Meswani has been promoted from Senior Vice President, Commercial Strategy and Operations to Chief Commercial Officer. Meswani held various management positions in retail and medicine at Novartis, Pharmacia, Biogen and most recently at Spark Therapeutics. At Spark, he was the director of US marketing and diagnostics.

F4 Pharma – To support F4 Pharma in the further development of its COVID-19 asset FX06 and to provide strategic guidelines, F4 Pharma has appointed a scientific advisory board composed of clinicians and scientists. The Scientific Advisory Board is headed by Kai Zacharowski, Director of the Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy at the University Hospital Frankfurt, and is currently President of the European Society for Anesthesiology. Other members are Nicolas Bréchot; Seiji Kojima; Patrick Meybohm; Peter Petzelbauer; and Roman Ullrich.

Inozym Pharma – Yves Sabbagh has been named Chief Scientific Officer of Inozyme Pharma. Sabbagh will replace David Thompson, who is retiring. Sabbagh will be responsible for expanding Inozyme’s proprietary pipeline by identifying and developing new therapeutics for monogenic and non-genetic diseases with abnormal mineralization. Prior to joining Inozyme, Sabbagh was Head of Research on Rare Kidney and Musculoskeletal Diseases at Sanofi. Previously, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation covering endocrine, renal and rare bone diseases, including strategy for bone indications. Prior to his corporate experience, he was an instructor at Harvard Medical School in the endocrine department.

VBL Therapeutics – Marc Kozin has been appointed Vice-Chair of the Israel-based VBL Board of Directors. Kozin will move to the role of chairman in 2021 and Bennett Shapiro, the current chairman of the board, will step down from that role. Shapiro remains on the board of directors. Kozin is currently Chairman of HealthCare Royalty Partners’ Strategy Advisory Board. Previously, Kozin was a career strategy advisor.

Agenus – Susan Hirsch is a member of the Agenus Board of Directors. Most recently, Hirsch was Managing Director at Nuveen. She previously held investment management positions at Jennison Associates, Lehman Brothers Global Asset Management and Delphi Asset Management.

NeuBase Therapeutics – Peter Nielsen was appointed to the scientific advisory board of NeuBase Therapeutics. Nielsen, the primary inventor of peptide nucleic acid technology (PNA), brings extensive experience in genetic medicine to the company. He is currently a professor at the University of Copenhagen where his laboratory focuses on PNAs related to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery and delivery of biopharmaceuticals.

MaxCyte – Brad Calvin has been promoted from his current position as Head of Global Commercial Operations to Chief Commercial Officer. In addition, Sarah Haecker Meeks joined the company as Vice President Business Development and Steve Nardi as Vice President Manufacturing and Engineering Operations. Prior to joining MaxCyte, Meeks was Vice President of Business Development at Synpromics, now part of AskBio. She was also the CSO at Adjuvant Partners. Nardi was previously Vice President, Worldwide Manufacturing at Iradimed Corporation.

OncoSec Medical – Sanda Aung has been named Chief Clinical Development Officer of OncoSec Medical Incorporated. Aung will be responsible for overseeing KEYNOTE-695, the company’s Phase IIb study evaluating the intratumoral delivery of its interleukin-12 (IL-12) -based immunotherapy Tavo (tavokinogenic teleplasmid) in combination with intravenous Keytruda (pembrolizumab) in patients with unresectable advanced melanoma.

NeuBase Therapeutics – Peter Nielsen was appointed to NeuBase’s scientific advisory board. Nielsen is currently a professor at the University of Copenhagen where his laboratory focuses on PNAs related to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery and delivery of biopharmaceuticals.

Genalyte – Ashraf Hanna has been named chief executive officer of Genalyte, a diagnostic and analysis company. Hanna will replace Cary Gunn, who will remain with the organization as founder and chief technology officer. Before joining Genalyte, Hanna was COO at Verily Life Sciences. Prior to this position, Hanna was CEO at ORIC Pharmaceuticals and previously Hanna was Head of Commercial and Medical Affairs Finance at Genentech and CFO of the Genentech Foundation.

Trevi Therapeutics – Shashank Rohatagi has been named Vice President of Pharmacology and Clinical Phrarmacokinetics. Shashank joins Trevi from Metrum Research Group, where he was Senior Principal Scientist in Clinical Pharmacology. Farrell Simon joins Trevi as Head of US Marketing. He joins Trevi from Pfizer where he was Chief of Staff to the Group President of Biopharma and a member of the executive team. Katherine S. Takaki has been hired to lead Trevi’s global regulatory affairs department, responsible for managing the supporting studies required to obtain regulatory approvals and all CMC-related activities. She joins the company from Iterum, where she played a similar role.

Processa Pharmaceuticals – Michael Floyd has been named COO of Processa. Floyd founded the early stage company Neurologic and was CEO of the North American subsidiary of Arpida Ltd. Floyd co-founded Elion Oncology, which licensed the PCS6422 to Processa.

Dew point therapeutics – Ameet Nathwani has been appointed CEO and member of the Board of Directors. Nathwani most recently served as Chief Medical Officer and Chief Digital Officer at Sanofi SA, where he led the company’s medical organization and, among other things, led the development of an industry-leading RWE (Real-World Evidence) data platform with embedded functions for artificial intelligence. Prior to Sanofi, Nathwani was Global Head of Medical Affairs at Novartis Pharmaceuticals AG. During his 12-year tenure at Novartis, he held various senior development and commercial positions.

Epirium Bio – Alexander Casdin has been appointed CFO of Epirum. Casdin was the founder, CEO and portfolio manager of Reneo Capital Management LP, a successful healthcare mutual fund. Previously, he was CFO of Sophiris Bio Inc. and Vice President of Finance at Amylin Pharmaceuticals. Sandy Mahatme, former CFO and CBO of Sarepta Therapeutics, Inc., will join Epirium’s Board of Directors and serve as Chairman of the Audit Committee. Mahatme is currently President, COO and CFO of a stealth company supported by ARCH Venture Partners.

NuCana– Bali Buralidhar has been appointed to the Board of Directors of NuCana plc.

Sofinnova partner – European VC firm Sofinnova named Joe Anderson a partner in the Sofinnova Crossover Fund. Previously, he was a partner at Abingworth LLP for over a decade, where he led venture investing in public companies and the creation of the company’s public equity fund. Most recently, Anderson was the co-founder and CEO of Arix Bioscience plc, a venture capital company listed on the London Stock Exchange.

Meissa vaccines – William Daly has been named CBO and Keith H. Wells has been named Chief Manufacturing Officer of Meissa. Daly’s experience in the biotech and pharmaceuticals industry includes leadership roles in business and corporate development at Ortho Biotech, Chiron, Allergan, Cougar Biotechnology, Halozyme Therapeutics, and Akebia Therapeutics. Before Meissa, he was Head of Business Development and Alliance Management at Portola Pharmaceuticals. Prior to joining Meissa, Wells was a scientific and technical advisor to BARDA on creating scale-up and regulatory pathways for medical countermeasures and vaccines. He also held positions of increasing responsibility in manufacturing and in process and product development at Acambis, the Government Services Division of the Salk Institute, and Merck and Co., Inc.

EFFECTOR therapeutics – Premal Patel was named CMO. Most recently, Patel was CMO at Lyell Immunopharma. Previously, he was Senior Vice President and Head of Early Clinical Drug Development at Juno Therapeutics.

Comments are closed.